Global Cord Blood (NYSE:CO) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:COGet Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Price Performance

NYSE CO opened at $1.01 on Friday. The firm’s 50-day moving average is $1.14 and its two-hundred day moving average is $1.38. Global Cord Blood has a 12 month low of $2.03 and a 12 month high of $5.50. The stock has a market capitalization of $122.77 million, a P/E ratio of 1.58 and a beta of 0.16.

About Global Cord Blood

(Get Free Report)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Featured Articles

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.